How Can the Marketing Authorization Holders Be Ready for the Implementation of the Joint Clinical Assessments in 2025?

Author(s)

Fernandes J, Mota M, Felix Parreia J
Exigo Consultores, Lisboa, 11, Portugal

Presentation Documents

OBJECTIVES: In January 2025, the European Commission will implement new health technology assessment (HTA) regulations, namely joint clinical assessments (JCA) for oncology medicines and advanced therapy medicinal products. Pricing and reimbursement decisions will remain under the purview of European Union (EU) HTA bodies, which will determine the added value for their health systems. Uncertainties persist for Marketing Authorization (MA) holders, demanding for refined management of the HTA process. This study aimed to understand how available evidence influences the HTA process up to reimbursement decisions.

METHODS: The study involved a comprehensive investigation into the EMA and INFARMED domains to gather relevant regulatory and evaluation criteria. A task force of experienced pharmacists and Health economists was established to discuss strategies for optimizing the preparation and prediction of the HTA process and to evaluate how existing evidence influences HTA.

RESULTS: The PICO framework (Population, Intervention, Comparators, Outcomes) produced by the JCA will be the foundation of the HTA process. For MA holders, predicting the PICO in advance and understanding the epidemiology of the disease will be essential for a successful HTA strategy, offering early insights and assessing alignment with each EU country settings. Align with this feasibility analysis, evidence gaps should also be identified, determining if there is enough evidence or if new evidence must be generated via methods like Network Meta-Analysis or Indirect Treatment Comparison. Understanding these gaps and their impact on decisions ensures MA holders effectively navigate the HTA process, aligning strategies with European healthcare systems' requirements.

CONCLUSIONS: Conducting a feasibility and gap analysis of existing evidence prior to obtaining the PICO framework will be crucial for MA holders and will enhance the predictability and risk management of the HTA process. A strategic and well-designed evidence plan can provide companies with an opportunity to mitigate PICO issues, limit uncertainty, and strengthen a JCA dossier.

Conference/Value in Health Info

2024-11, ISPOR Europe 2024, Barcelona, Spain

Value in Health, Volume 27, Issue 12, S2 (December 2024)

Code

HTA34

Topic

Clinical Outcomes, Health Policy & Regulatory, Health Technology Assessment

Topic Subcategory

Clinical Outcomes Assessment, Reimbursement & Access Policy, Value Frameworks & Dossier Format

Disease

No Additional Disease & Conditions/Specialized Treatment Areas

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×